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the G-BA website. 104 molecules that had gone through the AMNOG procedure were 
identified and further categorized in order to determine whether they had submit-
ted direct, indirect, or both types of comparisons. The G-BA publications by means 
of the classification score were used to source and quantify the outcome of the deci-
sion. RESULTS: 16 out of the 104 analyzed molecules were found to have submitted 
indirect comparisons. Out of these, the G-BA decisions recognized that 6 molecules 
had mild or significant overall added benefit. All of these 6 molecules presented both 
direct and indirect comparisons. On the other hand, molecules that only submitted 
indirect comparisons were found to have no additional benefit. The most common 
reasons for dismissals of indirect comparisons by IQWiG were the inappropriate 
patient population selection, the choice of inappropriate bridge comparators, and 
that population uniformity was not guaranteed. CONCLUSIONS: These results dem-
onstrate that submission of indirect comparisons alone are unlikely to result in a 
positive added benefit classification by IQWiG and the G-BA. However, if the indirect 
comparison is coupled with a direct comparison, the outcome of the assessment by 
the G-BA is more likely to result in a positive added benefit classification.
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OBJECTIVES: The first step in the route to reimbursement of a new product in 
Germany through the Arzneimittelmarkt-Neuordnungsgesetz (AMNOG) process is an 
assessment of additional benefit, conducted by the Gemeinsamer-Bundesausschuss 
(G-BA), which directly influences pricing negotiations. The G-BA may classify addi-
tional benefit of a new substance as major, considerable, minor or unquantifiable 
benefit or ‘no-benefit’. The analysis was conducted to compare trends of G-BA deci-
sions for new technologies and orphan technologies. Further analysis was conducted 
to identify differences in disease areas for companies planning a European launch 
of a new product. METHODS: A longitudinal database containing all additional ben-
efit decisions made by the G-BA was analyzed. Only one decision was published 
in 2011 so only data from 2012-2014 was explored for robustness. Orphan analysis 
was conducted for products with European Union (EU) orphan designation. Analysis 
by disease area classified products into British National Formulary (BNF) catego-
ries. RESULTS: In 2012-2014, G-BA assessed 99 new technologies and decided 48% of 
products had no additional benefit, 25% had minor additional benefit, 18% had consid-
erable additional benefit and the remainder had unquantifiable additional benefit. No 
technologies have been classified as having major additional benefit. G-BA are unable 
to classify an orphan treatment has having no additional benefit due to the nature of 
orphan designation thus no ‘no-benefit’ decisions of orphan products have been made 
but the G-BA decided that 38% (n= 16) of orphan products had unquantifiable benefit 
and 19% had considerable benefit (n= 3). 34% of decisions were for malignant disease 
and immunosuppression products. 12 of the 19 products found to have considerable 
benefit were for malignant disease and immunosuppression. CONCLUSIONS: A high 
proportion of G-BA decisions have been of no or unquantifiable benefit indicating 
that obtaining a high price in Germany is challenging but more likely for orphan, 
malignant disease and immunosuppression products.
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OBJECTIVES: Information regarding health technology assessment (HTA) require-
ments for orphan drugs in Asia Oceania is limited. The aim of our study was to com-
pare HTA evidentiary requirements for standard and orphan drug appraisals among 
7 Asia Oceania countries/regions. METHODS: A literature and policy review was con-
ducted to identify standard and orphan drug HTA requirements and processes for 
the following countries: Australia, Japan, South Korea and China (further divided into 
regions including Mainland China, Hong Kong, Singapore and Taiwan to capture the 
diverse healthcare markets included in the country). A modified Hutton Framework 
was used to descriptively assess the HTA and reimbursement processes in these 
7 countries/regions. RESULTS: Authorities in Asia Oceania are currently in various 
stages of HTA and reimbursement process development for standard and orphan 
drugs. Of the 7 countries/regions studied, Australia is the only country with distinct 
orphan drug HTA evidentiary requirements and processes compared to standard 
drugs. Cost-effectiveness evidence is required as part of South Korea’s standard HTA 
review, but incremental cost-effectiveness ratio (ICER) thresholds are more lenient 
for orphan drugs. In Hong Kong, orphan drugs are assessed by an independent expert 
review committee, and appraisal criteria weigh heavily on patient characteristics and 
perceived benefit. Several countries/regions include health economics in their stand-
ard HTA review: Taiwan (budget impact, comparative effectiveness) and Singapore 
(cost-effectiveness); both countries/regions have similar evidentiary requirements 
for orphan and standard drugs. Japan is in early stages of developing HTA procedures 
and requires minimal economic evidence in standard and orphan drug assessment. 
Mainland China does not have a centralized HTA process for standard and orphan 
drugs. CONCLUSIONS: Most Asia Oceania countries/regions are still developing their 
HTA policies. Due to lack of distinct orphan drug HTA procedures in Taiwan, Singapore, 
Mainland China, and Japan, obtaining reimbursement for drugs may require addi-
tional efficacy or health economic analyses.
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decreasing from 65% in 2005 (n= 17) to 47% in 2013 (n= 15) but then drastically improv-
ing to 82% in 2014 (n= 22). The BNF category with the highest recommendation rate 
was infections (88%, n= 102); conversely, the gastro-intestinal system category had 
the lowest recommendation rate (55%, n= 42). CONCLUSIONS: Results suggest that 
HTA trends in Scotland were reformed in 2014 by changes in the SMC process, which 
included the aim of improving patient access to cancer medications. Recent changes 
implemented by SMC as a result of the Routledge review may provide hope to compa-
nies preparing to navigate the SMC process with oncology, immunology or infection 
products, but companies with products in other areas should explore all considera-
tions through further analyses to maximise market access opportunities in Scotland.
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OBJECTIVES: The Scottish Medicines Consortium (SMC) recommend the use of 
cost-minimization analysis for: therapeutically equivalent treatments established 
through non-inferiority studies; indirect comparisons showing statistically insig-
nificant difference; or where cost-utility analysis shows extremely small quality-
adjusted life year differences between treatments. When a new medicine has 
identical benefits to the comparator, the SMC chooses the cheaper option. In 2014, 
the Office for Health Economics found that whilst the SMC does not specify a type 
of economic analysis for biosimilars, cost-minimization analysis had been used for 
all approved submissions. We examine longitudinal trends and probabilities of rec-
ommendation for any companies using cost-minimization analysis. METHODS: All 
analyses were based on a validated, longitudinal database of all recommendations 
from 2002 to 2014. SMC recommendations following full submission, resubmis-
sions or abbreviated submissions were reviewed to provide some insight into the 
considerations that companies should include in their strategic plans. RESULTS: 
Since 2010, there has been an increasing trend for the use of cost-minimization 
analysis with 35% of full submissions in 2014 using cost-minimization, as well as 
25% of resubmissions. Of the 68 cost-minimization submissions, 24 have received 
positive recommendation, 35 restricted and 9 not recommended. Cost minimiza-
tion has been used in the greatest proportion of respiratory submissions (47% of 
submissions, n= 8, 88% recommended) and infections (43% of submissions, n= 6, 
100% recommended) but most cost-minimization submissions are for endocrine 
treatments (30% of submissions, n= 11, 91% recommended). The recommendation 
rates per BNF category vary greatly with no distinct category having greater suc-
cess. CONCLUSIONS: A manufacturer is most likely to gain a restricted recom-
mendation following submission of cost-minimization analysis. There is no distinct 
BNF category that has a greater chance of success using cost-minimization analysis. 
To recommend with cost-minimization analysis, the SMC must be certain that the 
comparators are appropriate and effectiveness is comparable.
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OBJECTIVES: Considering official introduction of pharmacoeconomic require-
ments in Japanese healthcare policy in 2016, we aimed to assess whether the qual-
ity of pharmacoeconomic studies in Japan has been improved over time, and what 
aspects are in need for further improvement. METHODS: The literature review 
approach was taken for English-language articles via PubMed (Japan AND “Cost-
Benefit Analysis”[Mesh]) and Embase (Japan AND cost effectiveness), and also for 
Japanese-language via Web service of Japan Medical Abstracts Society (“hiyo-tai-
koka” in Japanese, which means “cost-effectiveness”), excluding review articles, 
commentaries, methodological studies, and letters. After eligibility screening, we 
eventually obtained 174 articles as subjects, which were summarized and assessed 
regarding the quality of reporting on whether to state the five factors explicitly: 1) 
study perspective, 2) reason of discount rate, 3) year of currency, 4) time horizon, and 
5) comparator. For each of those factors, we examined a proportion of satisfaction, 
i.e., a percentage of the articles having clearly described the target factor among all 
the articles. In addition, the proportions were compared by the other nominal fac-
tors such as founding source, intervention type, and QALY employment. RESULTS: 
The number of publications has been increasing over time. Over 60 % of studies, 
however, did not clearly disclose their funding sources. The studies without any 
funding disclosure revealed less satisfaction in each of the five factors. Those with 
disclosure of industry-funding had higher satisfaction rates compared to the studies 
with public-funding disclosure or without funding disclosure. Although the stud-
ies which employed QALY as the outcome measure earned high satisfaction of the 
five factors, no totally positive improvement was observed over time in terms of 
satisfaction for any of the five factors. CONCLUSIONS: The quality of reporting the 
Japanese health economic evaluations was not yet satisfactory, and remains further 
challenges for quality improvement to comply with the international standards.
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OBJECTIVES: The AMNOG assessment procedure requires that manufacturers sub-
mit indirect comparisons for the assessment of molecules in the absence of direct 
comparisons versus the G-BA appropriate comparator. The purpose of this study 
was to understand the role that indirect comparisons have in IQWiG’s assessment 
of added benefit and consequently also on the G-BA decision outcome. METHODS: 
The IQWiG assessments and G-BA evaluations through the AMNOG process from 
initial implementation to the end of 2014 were analyzed based on publications from 
